Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 80 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood-based assay Clear all
Recruiting Phase 2 Interventional

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

NCT06311214
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Enfortumab Vedotin, Immunohistochemistry Staining Method, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sacituzumab Govitecan, Trastuzumab Deruxtecan
Procedure · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
27
States / cities
Duarte, California • Encinitas, California • Irvine, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 18, 2026, 3:37 AM EDT
Recruiting Phase 2 Interventional

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

NCT06954805
View directory record Official record
Conditions
Lymphoma, Lymphoma, B-Cell
Interventions
Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, CAPP-seq
Drug · Device
Lead sponsor
Jennifer Amengual
Other
Eligibility
15 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 18, 2026, 3:37 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Diagnosis of Abdominal Pain Using RNA Levels: The NATURAL Study

NCT07579312
View directory record Official record
Conditions
Intra Abdominal Infections, Appendicitis Acute, Pyelonephritis, Diverticulitis, Epiploic Appendagitis
Interventions
TruNAV, an RNA-based blood test for host immune activation by infections
Diagnostic Test
Lead sponsor
True Bearing Diagnostics, Inc.
Industry
Eligibility
7 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 18, 2026, 3:37 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

NCT06090669
View directory record Official record
Conditions
Inherited Bone Marrow Failure Syndrome, Familial Platelet Disorder With Predisposition to Myeloid Malignancies
Interventions
imatinib, TruSight Oncology
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Phase 1 Interventional

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

NCT02779283
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions
Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Idarubicin, Idelalisib, In Vitro Kinase Inhibitor Assay, Leucovorin Calcium, Methotrexate, Methylprednisolone Sodium Succinate, Ponatinib Hydrochloride, Rituximab, Ruxolitinib Phosphate, Sorafenib Tosylate, Sunitinib Malate, Vincristine Sulfate
Drug · Device · Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 64 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Not applicable Interventional Results available

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

NCT02551718
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions
Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy
Other · Genetic · Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 18, 2026, 3:37 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

SPARC - Screening for Lung Cancer With Platelets Via an AI-enabled RNA-based Classifier

NCT07460440
View directory record Official record
Conditions
Lung Cancer, Lung Nodule
Interventions
Platelet RNA-based assay
Diagnostic Test
Lead sponsor
University of Utah
Other
Eligibility
21 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 18, 2026, 3:37 AM EDT
Terminated Phase 4 Interventional Results available

Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing

NCT02749292
View directory record Official record
Conditions
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions
Rituximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 82 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 18, 2026, 3:37 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

AGED Diagnostics Liver Disease Assessment

NCT06348563
View directory record Official record
Conditions
NASH With Fibrosis, NAFLD, Healthy
Interventions
AGED Multiple Target Assay in Healthy Controls, AGED Multiple Target Assay in NAFLD Participants, AGED Multiple Target Assay in Fibrosis Participants
Diagnostic Test
Lead sponsor
Active Genomes Expressed Diagnostics, Corp
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 18, 2026, 3:37 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery

NCT03064152
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Rotational Thromboelastometry
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 18, 2026, 3:37 AM EDT
Completed No phase listed Observational

Diagnosis of Bacteremia/Septicemia and Culture Negative Endocarditis by the Karius Sequencing-Based Infectious Disease Diagnostic Assay

NCT02988414
View directory record Official record
Conditions
Bacteremia, Septicemia
Interventions
Not listed
Lead sponsor
Karius, Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 18, 2026, 3:37 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant

NCT03570411
View directory record Official record
Conditions
CMV
Interventions
T-SPOT®.CMV Test
Diagnostic Test
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 18, 2026, 3:37 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Lyme Test Indication Combinations (LyTIC) Study

NCT03201042
View directory record Official record
Conditions
Lyme Disease
Interventions
PCR based assay, Serology based assay, Tcell based assay
Diagnostic Test
Lead sponsor
Oxford Immunotec
Industry
Eligibility
5 Years and older
Enrollment
410 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
60
States / cities
Redding, California • New London, Connecticut • Norwalk, Connecticut + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 18, 2026, 3:37 AM EDT
Recruiting Phase 1 Interventional

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

NCT07162038
View directory record Official record
Conditions
Hematologic Malignancies, Hematologic Neoplasms
Interventions
mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL), Fludarabine, Cyclophosphamide, Mycophenolate Mofetil, Sirolimus, CD19 Flow Cytometry Assay, CD19 Immunohistochemical Assay, Total Body Irradiation
Biological · Drug · Device + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Early Phase 1 Interventional

RANKL Inhibition and Breast Tissue Biomarkers

NCT03629717
View directory record Official record
Conditions
Breast Cancer Prevention, Mammographic Density
Interventions
Ultrasound-guided core needle biopsy, Denosumab, Blood draw, Calcium, Vitamin D
Procedure · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
35 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Not applicable Interventional Results available

Validation of the GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains

NCT02718157
View directory record Official record
Conditions
Streptococcus Agalactiae Infection
Interventions
Comparison between GenePOC PCR and Reference Method
Device
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Detroit, Michigan • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 18, 2026, 3:37 AM EDT
Completed No phase listed Observational

Screening Tests in Detecting Colorectal Cancer

NCT00025025
View directory record Official record
Conditions
Colorectal Cancer
Interventions
sample testing
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
65 Years to 80 Years
Enrollment
4,482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
65
States / cities
Tuscon, Arizona • Oakland, California • Aurora, Colorado + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 18, 2026, 3:37 AM EDT
Terminated No phase listed Observational

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

NCT03786107
View directory record Official record
Conditions
Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Metastatic Cervical Cancer
Interventions
Almac HER-Seq Assay
Diagnostic Test
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 18, 2026, 3:37 AM EDT
Recruiting Phase 2 Interventional

CMV Immunity Monitoring in Lung Transplant Recipients

NCT05708755
View directory record Official record
Conditions
Lung Transplant; Complications
Interventions
Cytomegalovirus T Cell Immunity Panel (CMV-TCIP), Donor-Derived Cell-Free DNA (dd-cfDNA) Assay, Valganciclovir
Device · Diagnostic Test · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 18, 2026, 3:37 AM EDT
Completed No phase listed Observational

Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx IGH Assay

NCT06112301
View directory record Official record
Conditions
B-Cell Lymphoproliferative Disorder
Interventions
IdentiClone Dx IGH (IC IGH Dx) Assay
Diagnostic Test
Lead sponsor
Invivoscribe, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 18, 2026, 3:37 AM EDT
Active, not recruiting No phase listed Observational

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

NCT02633111
View directory record Official record
Conditions
B-cell Non-Hodgkin Lymphoma, Aggressive
Interventions
collected at pre-treatment tumor biopsy, Peripheral blood tests, PET/CT
Other · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
12
States / cities
Miami, Florida • Rochester, Minnesota • Basking Ridge, New Jersey + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 18, 2026, 3:37 AM EDT
Completed No phase listed Observational

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors

NCT02747407
View directory record Official record
Conditions
Astrocytoma, Glioma, Oligodendroglioma
Interventions
Hepatitis A Vaccine, Laboratory Biomarker Analysis, Tetanus Toxoid Vaccine, Trivalent Influenza Vaccine
Biological · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 18, 2026, 3:37 AM EDT
Completed Not applicable Interventional

Establishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assay

NCT07099001
View directory record Official record
Conditions
Alzheimer Disease (AD), Cognitive Decline
Interventions
Educational materials on the Alzheimer's disease assay, Alzheimer's disease assay results
Other
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 18, 2026, 3:37 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Predictors of Aspirin Failure in Preeclampsia Prevention

NCT05709483
View directory record Official record
Conditions
Preeclampsia
Interventions
Aspirin
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 18, 2026, 3:37 AM EDT